Baxter's will be the same as Talecris, poor bioavailabiity and multiple injections, once per week. Any market share they get with the straight injectable would be good for a Halozyme since presumably it will all be switched over. If it gets to market it should give BAX a nice competitive advantage, win back some of the lost market share (that just caused the stock to get crushed) and then some.
Market Data 
Markets 
AI
